Federal Register / Vol. 69, No. 220 / Tuesday, November 16, 2004 / Notices 67149

Send comments to Susan G. Queen, 

Ph.D., HRSA Reports Clearance Officer, 

Room 14–33, Parklawn Building, 5600 

Fishers Lane, Rockville, MD 20857. 

Written comments should be received 

within 60 days of this notice.

Dated: November 8, 2004. 

Tina M. Cheatham, 

Director, Division of Policy Review and 

Coordination.

[FR Doc. 04–25403 Filed 11–15–04; 8:45 am] 

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Initial Review Group, Subcommittee 

D—Clinical Studies. 

Date: December 8–10, 2004. 

Time: 7 p.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Bethesda North Hotel and 

Conference Ctr., 5701 Marinelli Road, North 

Bethesda, MD 20852. 

Contact Person: William D. Merritt, PhD, 

Scientific Review Administrator, Research 

Programs Review Branch, National Cancer 

Institute, Division of Extramural Activities, 

6116 Executive Blvd., 8th Floor, Bethesda, 

MD 20892–8328, (301) 496–9767, 

wm63f@nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS)

Dated: November 8, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25345 Filed 11–15–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Initial Review Group Subcommittee 

C—Basic & Preclinical. 

Date: December 8–10, 2004. 

Time: 6 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Bethesda North Hotel and 

Conference Ctr., 5701 Marinelli Road, North 

Bethesda, MD 20852. 

Contact Person: Michael B. Small, PhD, 

Scientific Review Administrator, Research 

Programs Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, Room 8127, Bethesda, 

MD 20892, (301) 402–0996, 

smallm@mail.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS)

Dated: November 8, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25350 Filed 11–15–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Review of Research Project Cooperative 

Agreements (U01s). 

Date: December 9, 2004. 

Time: 8:30 a.m. to 6 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: Hotel Rouge, 1315 16th Street, NW., 

Washington, DC 20036. 

Contact Person: Keith A. Mintzer, PhD, 

Scientific Review Administrator, Review 

Branch, Division of Extramural Affairs, 

National Heart, Lung, and Blood Institute, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 7186, MSC 7924, Bethesda, MD 

20892, (301) 435–0280.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.389, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS)

Dated: November 8, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25349 Filed 11–15–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

67150 Federal Register / Vol. 69, No. 220 / Tuesday, November 16, 2004 / Notices 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

General Medical Sciences Special Emphasis 

Panel MBRS Support of Continuous Research 

Excellence. 

Date: December 1, 2004. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Bethesda, 

MD 20892, (Telephone conference call). 

Contact Person: Rebecca H. Johnson, PhD, 

Office of Scientific Review, National Institute 

of General Medical Sciences, National 

Institutes of Health, Natcher Building, Room 

3AN18, Bethesda, MD 20892, (301) 594–

2771, johnsonrh@nigms.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS)

Dated: November 8, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25344 Filed 11–15–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, Program 

Project. 

Date: November 30, 2004. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852, 

(telephone conference call). 

Contact Person: Mark Swieter, PhD, Health 

Scientist Administrator, Office of Extramural 

Affairs, National Institute on Drug Abuse, 

National Institutes of Health, DHHS, 6101 

Executive Boulevard, Suite 220, Bethesda, 

MD 20892–8401, (301) 435–1389.

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, Program 

Project. 

Date: December 7, 2004. 

Time: 2 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6101 

Executive Boulevard, Rockville, MD 20852, 

(telephone conference call). 

Contact Person: Paul A. Coulis, PhD, 

Health Scientist Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, National Institutes of Health, 

DHHS, 6101 Executive Boulevard, Suite 220, 

Bethesda, MD 20892–8401, (301) 443–2105.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse Research 

Programs, National Institutes of Health, HHS)

Dated: November 8, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25347 Filed 11–15–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel 

Enhancing State Capacity To Foster Adoption 

Of Science-Based Practices. 

Date: December 2, 2004. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Hotel, 5151 Pooks 

Hill Road, Bethesda, MD 20814. 

Contact Person: Teresa Levitin, PhD, 

Director, Office of Extramural Affairs, 

National Institute on Drug Abuse, NIH, 

DHHS, Room 220, MSC 8401, 6101 Executive 

Boulevard, Bethesda, MD 20892–8401, (301) 

443–2755.

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel Minority 

Institutions Drug Abuse Research 

Development Program (MIDARP). 

Date: December 6, 2004. 

Time: 9 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Khursheed Asghar, PhD, 

Chief, Basic Sciences Review Branch, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS, Room 200, MSC 

8401, 6101 Executive Boulevard, Bethesda, 

MD 20892–8401, (301) 443–2755.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse Research 

Programs, National Institutes of Health, HHS)

Dated: November 8, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25348 Filed 11–15–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting.